BIO vs. BMY
BIO (Bio-Rad Laboratories, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — BIO in Medical Devices, BMY in Drug Manufacturers - General. Over the past 10 years, BIO returned 7.52%/yr vs 0.55%/yr for BMY. At a 0.21 correlation, their price movements are largely independent.
Performance
BIO vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIO achieves a 1.04% return, which is significantly lower than BMY's 3.21% return. Over the past 10 years, BIO has outperformed BMY with an annualized return of 7.52%, while BMY has yielded a comparatively lower 0.55% annualized return.
BIO
- 1D
- 0.22%
- 1M
- 19.33%
- YTD
- 1.04%
- 6M
- -3.90%
- 1Y
- 41.36%
- 3Y*
- -6.32%
- 5Y*
- -12.05%
- 10Y*
- 7.52%
BMY
- 1D
- -0.89%
- 1M
- -6.46%
- YTD
- 3.21%
- 6M
- 15.38%
- 1Y
- 17.20%
- 3Y*
- -1.60%
- 5Y*
- 0.54%
- 10Y*
- 0.55%
BIO vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIO Bio-Rad Laboratories, Inc. | 1.04% | -7.77% | 1.74% | -23.21% | -44.35% | 29.61% | 57.54% | 59.34% | -2.70% | 30.94% |
BMY Bristol-Myers Squibb Company | 3.21% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between BIO and BMY is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.28 |
Correlation (All Time) Calculated using the full available price history since Feb 28, 1980 | 0.21 |
The correlation between BIO and BMY shifts across timeframes, from 0.21 (all time) to 0.31 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
BIO:
$8.25B
BMY:
$111.29B
BIO:
$6.24
BMY:
$3.57
BIO:
49.02
BMY:
15.27
BIO:
0.45
BMY:
0.87
BIO:
3.20
BMY:
2.29
BIO:
1.20
BMY:
5.55
BIO:
$2.59B
BMY:
$48.48B
BIO:
$1.34B
BMY:
$33.33B
BIO:
$746.20M
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIO vs. BMY — Risk / Return Rank
BIO
BMY
BIO vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bio-Rad Laboratories, Inc. (BIO) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIO | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.01 | 0.65 | +0.36 |
Sortino ratioReturn per unit of downside risk | 1.73 | 1.13 | +0.59 |
Omega ratioGain probability vs. loss probability | 1.23 | 1.13 | +0.09 |
Calmar ratioReturn relative to maximum drawdown | 1.21 | 1.35 | -0.14 |
Martin ratioReturn relative to average drawdown | 2.91 | 3.00 | -0.09 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BIO | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.01 | 0.65 | +0.36 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.32 | 0.02 | -0.35 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.22 | 0.02 | +0.20 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | 0.34 | -0.08 |
Drawdowns
BIO vs. BMY - Drawdown Comparison
The maximum BIO drawdown since its inception was -83.64%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for BIO and BMY.
Loading charts...
Drawdown Indicators
| BIO | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.64% | -72.03% | -11.61% |
Max Drawdown (1Y)Largest decline over 1 year | -28.86% | -13.68% | -15.18% |
Max Drawdown (3Y)Largest decline over 3 years | -48.76% | -36.85% | -11.91% |
Max Drawdown (5Y)Largest decline over 5 years | -73.77% | -47.67% | -26.10% |
Max Drawdown (10Y)Largest decline over 10 years | -73.77% | -47.67% | -26.10% |
Current DrawdownCurrent decline from peak | -62.93% | -21.63% | -41.30% |
Average DrawdownAverage peak-to-trough decline | -27.73% | -22.38% | -5.35% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.98% | 6.14% | +5.84% |
Volatility
BIO vs. BMY - Volatility Comparison
Bio-Rad Laboratories, Inc. (BIO) has a higher volatility of 15.41% compared to Bristol-Myers Squibb Company (BMY) at 6.13%. This indicates that BIO's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIO | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.41% | 6.13% | +9.28% |
Volatility (6M)Calculated over the trailing 6-month period | 28.44% | 18.48% | +9.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 41.28% | 26.65% | +14.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 37.26% | 23.97% | +13.29% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.03% | 25.25% | +8.78% |
Dividends
BIO vs. BMY - Dividend Comparison
BIO has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.59%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIO Bio-Rad Laboratories, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.59% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Financials
BIO vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Bio-Rad Laboratories, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BIO vs. BMY - Profitability Comparison
BIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bio-Rad Laboratories, Inc. reported a gross profit of 309.40M and revenue of 592.10M. Therefore, the gross margin over that period was 52.3%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
BIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bio-Rad Laboratories, Inc. reported an operating income of 34.10M and revenue of 592.10M, resulting in an operating margin of 5.8%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
BIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bio-Rad Laboratories, Inc. reported a net income of -527.10M and revenue of 592.10M, resulting in a net margin of -89.0%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
Frequently Asked Questions
BIO and BMY have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIO has higher volatility (15.41%) compared to BMY (6.13%). In terms of maximum drawdown, BIO dropped -83.64% vs BMY's -72.03%.
BIO currently has the higher Sharpe Ratio (1.01 vs 0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIO and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer